本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
中國香港首度於荷蘭設計周設展，將中國香港最新的循環設計及可持續發展項目帶到荷蘭，再通過虛擬網絡推廣至國際 香港設計((囊))精選14個設計項目，了解循環設計下的創新商業模式和思維，如何適應並克服「雙老化」、高度商業化和消費主義、土地短缺、堆填區飽和、提升社會包容度等困難和挑戰，為中國香港這個亞洲中心帶來更多成長和發展機會。 香港2023年12月4日 /美通社/ -- 由香港設計中心旗下的 dX 設計交流計劃（dX）呈獻、香港特別行政區政府「創意香港」贊助的「香港設計((囊))」展覽，於荷蘭燕豪芬舉行在2023年10月21日至29日期間舉辦的荷蘭設計周中引起廣泛關注。香港設計中心特意將「香港設計((囊))」製作成VR虛擬展覽，讓更多國際觀眾也能深入了解中國香港最新的循環設計及可持續發展項目，促進國際間就循環經濟的焦點討論注入亞洲視野。 「香港設計((囊))」展覽一共展出14個設計項目，呈現豐富的循環設計面貌之餘，亦突顯香港獨特的城市景觀，以及中西交滙的文化、社會及經濟發展特色。一眾香港設計師的獨到設計，為國際及亞洲城市共同面對的困境帶來嶄新的亞洲視點。當中觸及的城市問題包括高度商業化和消費主義、土地短缺、「雙老化」（即人口老化和樓宇老化）、廢物處理、對提升社會包容度的需求等等。 「香港設計((囊))」展覽採用迴旋形設計，以呼應策展主題中「循環」和「無限」的概念，充分體現展出項目和循環設計的精神。展覽中精選的設計項目以「消費主義及廢物」、「科技與物料」和「可持續性與包容性」三大主題，並根據七大元素呈現：減少（REDUCE）、修補（REPAIR）、重用（REUSE）、回收（RECYCLE）、再造（REMAKE）、再設計（REDESIGN）和活化（REVITALISE），涵蓋這些來自不同設計領域的項目。是次展覽由香港設計中心策劃，在BODW與荷蘭今年的國家伙伴計劃下，為香港和荷蘭設計師帶來一次絕佳的交流機會。 香港設計中心業務發展及項目總監兼「香港設計((囊))」策展人林美華女士表示：「透過展覽中的作品，我們嘗試探索香港這座『垂直城市』如何以源源不絶的創新精神和重塑力量回應當下各種挑戰。『循環』一詞有著『無限』的意味，因此展覽邀請觀眾一起觀察不斷變化的設計趨勢和影響，透過發問、思考，不斷累積各自經驗，發掘更多的可能性和機會，從而建立雙向而持久的對話，共同應對氣候變化及提升包容度等環球議題。」 dX一向致力培育人才，鞏固「中西交滙」的香港作為國際文化交流中心的地位。因此今次在展覽以外，亦特意策劃各式各樣的公眾及設計活動，以進一步深化dX的使命。精彩活動包括「香港設計((囊))」展覽期間由參展香港設計師主持的導賞團，提供即席與現場觀眾交流的機會；2023年10月26日舉行的dX設計對談，透過主題式討論與公眾交流和業界互動。與此同時，今次親身出席荷蘭設計周的參展香港設計師及創意團隊，亦在荷蘭開展各自的「啟發之旅」，走訪當地設計師工作室及機構，作為豐富文化交流旅程的一部分，並於回港後在2023年11月30日舉辧分享會，與香港業界分享交流心得。在是次實體展覽及相關活動結束後，現在公眾亦可登上dX.hkdc Instagram或香港設計中心官網參觀「香港設計((囊))」VR虛擬展覽。 參與今次海外展覽的創意團隊包括（排名不分先後）：B+G Design Co.；CoDesign Ltd.；Invisible Company吳珈蔚；Beyond Vision International (BVI) Rico Chan博士；香港建築師學會雙年展基金會及旗下2019年港深城市\建築雙城雙年展*總策展人胡燦森；香港設計中心旗下設計#香港地總策展人及項目總監林美華；Editecture翟凱怡和許恒達；Boundless姜美而；陳韻淇 Kay Chan Wan Ki；Kibo周張穎雯和Caroline Tronel；Fashionary 葉智雄；Project Futurus文慧妍和蔡盈楓；香港紡織及成衣研發中心；以及葉頌文環保建築師事務所。 荷蘭設計周於2002年首辦，時至今日已發展成為歐洲北部最大型的設計活動，向當地及海外超過355,000名觀眾呈現超過2,600個設計師的作品和概念。在香港設計中心舉辦的設計營商周（BODW）國家伙伴計劃下，荷蘭設計周成為荷蘭與中國香港一個絕佳的設計交流平台。 「香港設計((囊))」為第五屆的dX設計交流計劃。在香港設計中心致力推動香港成為亞洲區內國際設計中心的努力下，dX積極連結本地人才和國際機遇，啟發他們創造具國際影響力的設計，探索設計共創的可能性。dX至今已到訪曼谷、墨爾本、東京和加州等城市。 請於以下連結參觀「香港設計((囊))」VR虛擬展覽：https://my.matterport.com/show/?m=pQST8jfRtBL
LONDON, Sept. 18, 2023 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today announced it has joined the International Emissions Trading Association (IETA) as the first member with risk capital capabilities. IETA is a non-profit organization that seeks to establish an international framework for trading in greenhouse gas emission reductions while balancing economic efficiency with environmental integrity and social equity. Aon's membership in IETA supports its purpose to shape decisions for the better — to protect and enrich the lives of people around the world. Innovation in data, analytics and risk transfer solutions enable Aon to help clients accelerate their investments in decarbonization and climate resiliency and aid in the transition to a lower-carbon economy. Aon seeks to develop further insights on carbon market developments and trends as well as emerging rules and regulations and help develop market-based climate solutions for greenhouse gas emissions reductions that can impact an organization's ability to meet net-zero targets. "Carbon credits are an important part of the journey to net zero," said Dirk Forrister, president and CEO of IETA. "As with any emerging market, the need for clear information, actionable advice and robust support is vital for companies seeking to leverage the potential of carbon markets. We welcome Aon's determination to assist business' journey to reduce emissions and transition to a lower-carbon economy." Well-established carbon markets are essential to the ability of businesses to mitigate the effects of climate risk. However, there are pressing challenges of building trust, ensuring reliability, and managing risk and volatility, which IETA and its members are working to address. Aon will contribute to the continuing efforts of IETA in building integrity in greenhouse gas emissions trading and market activities. Natalia Moudrak, North America leader for Aon's Climate team, will join IETA's Voluntary Carbon Markets working group, and Stephanie Betts, head of alliances, coalitions and reporting for Aon, will join the organization's Natural Climate Solutions working group. Together, they will support IETA's drive toward transparency and enhanced governance of the carbon market in both emerging markets and developed economies. "The voluntary carbon market is rapidly expanding and represents a significant opportunity to drive environmental and social impacts on the climate transition. Risk solutions can help bring an additional layer of confidence to this market, helping accelerate investments into high-integrity decarbonization solutions," Moudrak said. "Aon's insights into developments in the voluntary carbon market allow us to better advise our clients on their transition to a low-carbon future as we navigate new forms of volatility." Betts added, "Climate risks are complex and interconnected and require companies, associations and governments to work together to mitigate. Active collaboration has never been more important between the public and private sectors. Compelling market incentives will help drive a large-scale reallocation of capital, creating new opportunities and stronger outcomes. We believe that a thriving, trusted carbon market is a cornerstone of this new economy and we look forward to collaborating with IETA and its members on these efforts." During New York Climate Week, Aon will host a series of panel discussions and convene experts from business, government and the social sector to explore the risks and opportunities of the climate transition. Access Aon's insights and capabilities on managing climate and sustainability here. About AonAon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Our colleagues provide our clients in over 120 countries and sovereignties with advice and solutions that give them the clarity and confidence to make better decisions to protect and grow their business. Follow Aon on LinkedIn, Twitter, Facebook and Instagram. Stay up-to-date by visiting the Aon Newsroom and sign up for News Alerts here. Media ContactNadine Youssefmediainquiries@aon.comToll-free (U.S., Canada and Puerto Rico): +1 833 751 8114International: +1 312 381 3024
Financing lead by Particle Future SAN JOSE, Calif., Aug. 25, 2023 /PRNewswire/ -- FranklinWH Energy Storage Inc. ("FranklinWH"), a leader in whole-home energy management, today announced that it secured $25 million in Series B funding. The financing round was led by Particle Future to propel FranklinWH's growth and solidify its position as an innovative leader in delivering whole-home energy freedom for every household in the United States and Puerto Rico. The funding comes as the U.S. is in the middle of an energy transformation. More than 70% of the U.S. electricity grid is more than 25 years old and vulnerable to disruption. The U.S. Department of Energy announced that two thirds of the country is at risk of a power outage in summer 2023 alone. Today's changing and complicated energy landscape must support bi-directional energy flow and a variety of renewable energy sources. These developments and other factors, such as infrastructure investments via the Inflation Reduction Act, are paving the way for the 'age of the battery.' The funding will support FranklinWH's mission to create a seamless living experience by integrating diverse energy sources with home battery technology. FranklinWH envisions a world where energy independence is within everyone's reach, regardless of geographical or socio-economic status. Funding will allow the company to focus on solving the challenge of energy storage and management, which has been a limiting factor in the broader adoption of renewable energy. FranklinWH plans to allocate the invested funds to expand its R&D capabilities, optimize supply chain and scale up its company operations and sales network. "The best days of renewable energy are ahead of us," said Gary Lam, Co-Founder of FranklinWH. "Battery storage systems are positioned to expand in the energy market because they are strong alternatives to the vulnerable, outdated and expensive energy grid. This funding from Particle Future will help FranklinWH advance home battery technology and make renewable energy options more accessible." Founded in 2019, FranklinWH is originally funded by Sequoia Capital and committed to bringing homeowners energy independence. Its team is well experienced in energy systems and designed the Franklin Home Power (FHP) solution, a whole-home energy management system with AC-coupled storage. After just over one year on the American market, FranklinWH has onboarded over 1,000 installation companies through its FranklinWH Certified Installer program. FranklinWH is AVL listed with multiple financial institutions, and its tier one lithium iron phosphate (LFP) cell access allows it to bring homeowners, installers and distributors the highest-value of battery products. FHP is FranklinWH's marquee offering to homeowners providing flexibility and energy independence to homes. FHP's powerful, integrated home energy management system consists of the aPower battery — offering the highest LFP AC capacity on the market — and the aGate, an intelligent power control system that creates maximum home comfort. The solution is pre-assembled for fast and easy installation. "Solar panels had their day in the sun over the past few years, but homeowners are becoming interested in pairing solar with other energy efficient technologies to balance a home's energy supply," said Vincent Ambrose, Chief Commercial Officer at FranklinWH. "Our Franklin Home Power system is designed to integrate seamlessly with existing infrastructure and a mix of energy sources, including traditional generators and renewable energy technologies. This provides a smooth, pragmatic transition that minimizes disruption in households adopting renewable energy." For more information about FranklinWH, please visit the website. About FranklinWH FranklinWH Energy Storage is the manufacturer of the Franklin Home Power system. FranklinWH is a research-driven company focused on next-generation residential energy management and storage solutions. Founded in 2019 and headquartered in the San Francisco Bay Area, FranklinWH's team has decades of experience in energy systems, from design, through manufacturing, to sales and installation. FranklinWH is also on the Approve Vendor's List with multiple financial institutions. Learn more about how homeowners can achieve energy independence at franklinwh.com. Media Contacts:media@franklinwh.com
LONDON, July 13, 2023 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, and Mergermarket, a provider of intelligence, data and analysis of global M&A, today released the latest edition of their M&A Risk in Review series, covering the first half of 2023. According to Aon and Mergermarket's survey of 50 senior executives from corporate development teams, private equity firms and investment banks, dealmakers remain upbeat about the health of the M&A arena. Nearly half of respondents - 46 percent - expect the number of deals globally to increase somewhat or significantly over the next 12 months compared to 2022. A further 20 percent expect figures for the year ahead to remain in line with current volumes. "We are excited to share these important market insights that can help shape better decisions as the deal environment continues to evolve and poses new challenges," said Gary Blitz, global co-CEO of Aon's M&A and Transaction Solutions. "By taking this broad view of the M&A landscape, dealmakers are better able to understand and respond to critical risks that can have an impact on a deal's success." This does not necessarily mean that sailing will be smooth – from climate, tax and cyber risk to market dislocation and geopolitical uncertainty, rarely before have M&A strategies had their mettle tested by such varied forms of volatility simultaneously. Dealmakers must be proactive in controlling whatever risks they can, install mitigation plans for those outside their direct influence and use risk transfer solutions when available. "Dealmaking is about balancing risk and return," said Alistair Lester, global co-CEO in Aon's M&A and Transaction Solutions. "With strong risk mitigation processes in place, including a multi-disciplined approach to due diligence and the strategic use of insurance capital, dealmakers are able to transform their risk into opportunity to improve their deal outcomes." The M&A Risk in Review series explores these dynamics in detail, reporting on investors' expectations for global M&A over the next 12 months, standout sectors and the key risks they see – and how best to mitigate them. Additional highlights of the report include: 68 percent of respondents identify Technology, Media and Telecom (TMT) as likely to be the most prolific generator of M&A activity over the next 12 months. Conversely, the financial services sector is forecast by 32 percent of respondents to be the least prolific sector for dealmaking. 72 percent of respondents expect financing conditions to worsen compared to 2022, including 38 percent who expect them to become much more challenging. In response, dealmakers are turning toward alternative financing sources, including private equity (64 percent) and non-bank lending (38 percent). 96 percent of respondents expect Environmental, Social and Governance (ESG) scrutiny in deals to increase over the next three years, including 48 percent who expect it to increase significantly. In addition, 24 percent say environmental litigation creates the most concern in respect of potential disputes in a deal. For more information, access the M&A Risk in Review here. About AonAon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Our colleagues provide our clients in over 120 countries and sovereignties with advice and solutions that give them the clarity and confidence to make better decisions to protect and grow their business. Follow Aon on LinkedIn, Twitter, Facebook and Instagram. Stay up-to-date by visiting the Aon Newsroom and sign up for News Alerts here. Media Contactsmediainquiries@aon.comToll-free (U.S., Canada and Puerto Rico): +1 833 751 8114International: +1 312 381 3024 Sarah Tremallo, JConnelly+1 908 967 0381stremallo@jconnelly.com
DUBLIN, April 28, 2026 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today released its inaugural Human Capital Trends Study, revealing a critical gap at the center of enterprise AI strategies: organizations recognize their people will drive AI success, but they are not investing in their people strategies. According to the study, 88 percent of employers agree that AI will require their workforce to develop new skills and rank human capabilities such as adaptability, leadership and change management as the most critical drivers of success in the next three years, even ahead of technical skills. While 73 percent of organizations have already deployed or are piloting AI programs, only 18 percent report that most of their workforce has participated in AI reskilling or upskilling programs in the past year. The gap is most visible where AI strategies are advanced in isolation — without clear alignment to business objectives, operating models or the workforce capabilities required to deliver them. Only 28 percent of organizations surveyed have hired employees with AI expertise, underscoring a continued reliance on developing talent from within. The result is a disconnect between what organizations know will drive success and how they are prioritizing resources — one that is emerging as a material risk to enterprise value. "The winners in the application of AI will lead with world-class people strategies," said Greg Case, president and CEO of Aon. "AI represents a historic opportunity for growth, particularly for organizations that approach transformation by integrating people and technology — so they evolve in lockstep. By closing the gap between ambition and readiness, leaders can act with confidence, strengthen long‑term resilience and win today and in the future." Workforce Readiness Is Shaping How AI Performs at Scale As organizations invest heavily in AI, many are deploying technology faster than they are building the skills, structures and human support needed to make it effective. The study finds that many organizations continue to prioritize short-term efficiency gains over developing the workforce capabilities needed to sustain impact. Eighty percent of organizations cite automating routine tasks as a primary objective for AI; only 35 percent prioritize workforce upskilling and reskilling. At the same time leaders acknowledge that human capabilities will increasingly determine AI success, 84 percent of employers say human strengths will become more important as automation increases and 37 percent of leaders identify future workforce skills gaps as their top concern over the next five to 10 years. Together, these findings point to a clear misalignment: organizations are accelerating automation while underinvesting in the people required to operationalize it differently. The study underscores that people risks are business risks. Workforce readiness is a critical factor in translating AI investment into consistent execution. When leaders lack clear expectations and guardrails for how AI is used, or when readiness efforts lag behind deployment, organizations face slower adoption, fragmented decision-making and greater operational and reputational exposure — limiting the performance gains AI is expected to deliver. "AI success ultimately depends on their people, but most are still investing primarily in the technology. That disconnect is where opportunity is lost," said Byron Beebe, CEO of Human Capital for Aon. "Closing the readiness gap takes a coordinated approach — building skills and confidence, setting clear governance and enabling leaders to guide change — so technology investments translate into sustainable performance and resilience." Organizations that Operationalize AI Also Invest in Their People The study also finds that organizations further along in AI deployment demonstrate stronger alignment between their technology and workforce strategy. For example, organizations that have fully deployed AI are more than twice as likely to describe their leadership's commitment to employee wellbeing as strong and visible compared to those who've discussed AI but haven't taken action. This suggests that the ability to operationalize AI is closely tied to a broader focus on human sustainability, engagement and trust – factors that enable organizations to scale change effectively and sustain performance over time. Turning AI Investment into Impact Beyond identifying risk, Aon's Human Capital Trends Study outlines practical actions organizations can take to close the readiness gap and unlock value from AI. These include aligning AI strategy with workforce planning; assessing AI skills and future capability needs and investing in structured, organization-wide reskilling and upskilling strengthening leadership capability to guide change with clear governance and guardrails; and using more mature, connected people data and analytics to make smarter decisions about where to invest. Organizations that act decisively can build more resilient, confident and productive workforces and fully realize the promise of AI. As AI adoption accelerates, organizations face a clear choice: continue prioritizing technology alone or invest equally in the workforce required to make it effective. Those that close the gap between intention and action by building skills, strengthening culture and enabling leadership will be best positioned to convert AI into a durable competitive advantage. Read the full 2026 Human Capital Trends Study here. ENDS About Aon Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses. Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon's newsroom and sign up for news alerts here. Media Contact mediainquiries@aon.comToll-free (U.S., Canada and Puerto Rico): +1 833 751 8114International: +1 312 381 3024 Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues in over 120 countries provide our clients with the clarity and confidence to make better risk and people decisions that protect and grow their businesses. Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon’s newsroom and sign up for news alerts here.
CHENGDU, China, April 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study SKB264-II-06/MK-2870-002 of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), in combination with MSD's[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[2]), were selected for oral presentation at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting in San Juan, Puerto Rico. The data were presented by Professor Xiaohua Wu of Fudan University Shanghai Cancer Center. Ovarian cancer This presentation reported, for the first time, important data on sac-TMT as maintenance treatment in breast cancer susceptibility gene (BRCA) wild-type, second-line platinum-sensitive recurrent ovarian cancer. Among the 40 patients enrolled in the ovarian cancer cohort, 27 received sac-TMT (4 mg/kg, every other week (Q2W)) in combination with pembrolizumab, and 13 received sac-TMT (5 mg/kg, Q2W) in combination with pembrolizumab. Among the enrolled patients, 70% had prior bevacizumab therapy, and 58% had prior PARP inhibitor therapy. The median follow-up was 22.2 months (data cutoff date: November 17, 2025). The data showed that median progression-free survival (PFS) in the overall population was 20.9 months; median overall survival (OS) was not reached; and the 12-month OS rate was 92%. Additionally, the adverse events of sac-TMT in combination with pembrolizumab were manageable. The most common treatment-related adverse events (TRAEs) were anemia, stomatitis, and decreased neutrophil count. No deaths or discontinuations due to sac-TMT-related TRAEs was reported. The study results showed that sac-TMT in combination with pembrolizumab as maintenance therapy for platinum-sensitive recurrent ovarian cancer demonstrated positive efficacy signals and a favorable safety profile, providing important evidence for further clinical exploration of this combination regimen in the ovarian cancer population. Cervical cancer A total of 68 patients with previously treated second-line or third-line recurrent or metastatic cervical cancer were enrolled in the cervical cancer cohort to receive sac-TMT at doses of 3 mg/kg, 4 mg/kg, or 5 mg/kg Q2W in combination with pembrolizumab. Among the enrolled patients, 57% had prior bevacizumab therapy, and 51% had prior immunotherapy. The median follow-up was 24.7 months (data cutoff date: November 17, 2025). The data showed that after treatment with sac-TMT in combination with pembrolizumab, the objective response rate (ORR) in the total population was 51% and 54% in IO-pretreated population. The median PFS was 7.3 months and the median OS reached 18.9 months in the total population. Furthermore, the safety profile of sac-TMT in combination with pembrolizumab was manageable, with no new safety signals identified and no deaths due to TRAEs. The study results demonstrated promising and durable antitumor activity with a manageable safety profile in patients with pre-treated second-line or third-line recurrent or metastatic cervical cancer receiving sac-TMT in combination with pembrolizumab, providing robust data to support further clinical development. About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan). To date, four indications for sac-TMT have been approved and marketed in China for: EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications listed above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinical benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA. Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing Phase III global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. [1] MSD is the tradename of Merck & Co., Inc, Rahway, NJ, USA. [2] KEYTRUDA® (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
A12 藝術空間
RICO
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
